Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 14/20 | 0.61 |
| ▸ | WDR91 | A4D1P6 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | PRNP | P04156 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3310110 | 0.94 | F10 (0.56) | F10LMNAMAPK1KMT2ANPC1 | |
| SCHEMBL3310161 | 0.86 | F10 (0.57) | F10LMNAMAPK1KMT2AMCHR1 | |
| SCHEMBL3312666 | 0.86 | F10 (0.57) | F10LMNAMAPK1KMT2AMCHR1 | |
| SCHEMBL3309468 | 0.86 | F10 (0.57) | F10LMNAMAPK1KMT2AMCHR1 | |
| SCHEMBL3307351 | 0.86 | F10 (0.57) | F10LMNAMAPK1KMT2AMCHR1 | |
| SCHEMBL3308187 | 0.85 | F10 (0.56) | F10LMNAMAPK1KMT2AMCHR1 | |
| SCHEMBL3305721 | 0.85 | F10 (0.56) | F10LMNAMAPK1KMT2AMCHR1 | |
| SCHEMBL3306427 | 0.85 | F10 (0.56) | F10LMNAMAPK1KMT2AMCHR1 | |
| SCHEMBL13394921 | 0.83 | F10 (0.50) | F10WDR91LMNAMAPK1KMT2A | |
| SCHEMBL3309229 | 0.83 | F10 (0.50) | F10WDR91LMNAMAPK1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100099664-A1 | SUBSTITUTED PYRROLIDINE AMIDES, THE PRODUCTION THEREOF, AND THE USE THEREOF AS MEDICATIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099664-A1 | SUBSTITUTED PYRROLIDINE AMIDES, THE PRODUCTION THEREOF, AND THE USE THEREOF AS MEDICATIONS | DDC, GLS, UROD | F10 2924/4885WDR91 2351/4885LMNA 3711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.